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Chongqing Medical University, Chongqing, ChinaAbstractWith the aim of gathering temporal trends on bacterial epidemiology and resistance frommultiple laboratories in China, the CHINET surveillance
systemwas organized in 2005. Antimicrobial susceptibility testingwas carried out according to a uniﬁed protocol using the Kirby-Bauer method or
automated systems. Results were analyzed according to Clinical and Laboratory Standards Institute (CLSI) 2014 deﬁnitions. Between 2005 and
2014, the number of bacterial isolates ranged between 22 774 and 84 572 annually. Rates of extended-spectrum β-lactamase production
among Escherichia coli isolates were stable, between 51.7 and 55.8%. Resistance of E. coli and Klebsiella pneumoniae to amikacin, ciproﬂoxacin,
piperacillin/tazobactam and cefoperazone/sulbactam decreased with time. Carbapenem resistance among K. pneumoniae isolates increased
from 2.4 to 13.4%. Resistance of Pseudomonas aeruginosa strains against all of antimicrobial agents tested including imipenem and meropenem
decreased with time. On the contrary, resistance of Acinetobacter baumannii strains to carbapenems increased from 31 to 66.7%. A marked
decrease of methicillin resistance from 69% in 2005 to 44.6% in 2014 was observed for Staphylococcus aureus. Carbapenem resistance rates in
K. pneumoniae and A. baumannii in China are high. Our results indicate the importance of bacterial surveillance studies.
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nized. The data, in a uniﬁed format, were collected from
microbiology laboratories and input into a central database
using WHONET software [1]. These data provided a
comprehensive national picture of resistance. In this analysis,
we reported the signiﬁcant changes and trends in antimicrobial
resistance of clinically important pathogens from the CHINET
surveillance system.Materials and MethodsBacterial strains, culture media and species
identiﬁcation
All aerobic bacteria (excluding anaerobic bacteria, fungi and
mycobacteria) collected from outpatients and inpatients in 19
hospitals were obtained in the CHINET surveillance system for
a 10-year period between 2005 and 2014 (two hospitals
dropped out in 2012). Most of the hospitals included are the
largest in each province or city; altogether, they represent 14
provinces or cities (about six hundred million population). In
order to avoid duplicate counts, only one isolate from the same
species was included per patient, based on the personal iden-
tifying code and hospital, per year. For coagulase-negative
Staphylococcus and viridans Streptococci, only isolates collected
from blood and cerebrospinal ﬂuid were included in the anal-
ysis. Species identiﬁcation of the isolates was performed by
standard biochemical methods, the API 20E system or the Vitek
2 automated system (bioMérieux, Marcy l’Etoile, France).
Antimicrobial susceptibility testing
The antibiotic susceptibilities of clinical isolates were deter-
mined using the disk diffusion method according to the Clinical
and Laboratory Standards Institute (CLSI) criteria (http://ncipd.
org/control/images/NCIPD_docs/CLSI_M100-S24.pdf), or theTABLE 1. Percentage of targeted ﬁve species among total numb
outpatients)
Year
No.
hospitals Total
Escherichia
coli
Klebsiella
pneumoniae
Pseudomon
aeruginosa
n % n % n
2005 8 22 774 3758 16.5 2234 9.8 2323
2006 9 33 945 6072 17.9 3452 10.2 4752
2007 12 36 001 6524 18.1 3037 8.4 3988
2008 12 36 216 6678 18.4 3435 9.5 4130
2009 14 43 670 7992 18.3 4556 10.4 4912
2010 14 47 850 9225 19.3 5529 11.6 5080
2011 15 59 287 11 860 20.0 6981 11.8 6012
2012 15 72 397 14 154 19.6 9621 13.3 7271
2013 16 84 572 16 794 19.9 12 121 14.3 8257
2014 17 78 955 16 511 20.9 11 308 14.3 7471
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instrument speciﬁcations, and the results were interpreted
according to CLSI criteria (http://ncipd.org/control/images/
NCIPD_docs/CLSI_M100-S24.pdf). During the 10-year sam-
pling period, the methodologies used were consistent in all
participating hospitals. Extended-spectrum β-lactamase (ESBL)
production was identiﬁed by clavulanic acid synergy test (http://
ncipd.org/control/images/NCIPD_docs/CLSI_M100-S24.pdf).
No minimum inhibitory concentration data were available.
Reference strains
Staphylococcus aureus ATCC 25923, Enterococcus faecalis ATCC
29212, Escherichia coli ATCC 25922 and Pseudomonas aeruginosa
ATCC 27853 were included to ensure reproducibility of the
antibiotic susceptibility testing procedure.ResultsPercentage of targeted ﬁve species
The total number of bacterial isolates was between 22 774 and
84 572 annually. There were no changes in the ratio between
specimen types during the study period. The percentage of the
targeted ﬁve species among total number of all reported iso-
lates is shown in Table 1. The ﬁve selected species accounted
for 51.9 to 60.3% of all isolates (Table 1).
Escherichia coli
The rate of ESBL-producing isolates was stable, from 51.7% in
2006 to 55.8% in 2014 (Fig. 1). A marked decrease of resis-
tance was seen for amikacin from 11.9 to 4%. However, a
marked increase of resistance was seen for cefotaxime and
ceftazidime from 52.2 to 63.2% and from 14.9 to 30.9%,
respectively. Piperacillin/tazobactam, cefoperazone/sulbactam
and ciproﬂoxacin resistance levels decreased from 6.2 toer of all reported isolates (isolated from both inpatients and
as Acinetobacter
baumannii
Staphylococcus
aureus
Total percentage
of targeted ﬁve
species
% n % n %
10.2 2095 9.2 1440 6.3 52.0
14.0 2968 8.7 1799 5.3 56.1
11.1 3157 8.8 1963 5.5 51.9
11.4 3625 10.0 1987 5.5 54.8
11.2 4796 11.0 2167 5.0 55.9
10.6 5523 11.5 2302 4.8 57.8
10.1 6723 11.3 3033 5.1 58.4
10.0 8739 12.1 3519 4.9 59.8
9.8 10 120 12.0 3672 4.3 60.3
9.5 8769 11.1 3172 4.0 59.8
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TABLE 2. Resistance rates (%) of Escherichia coli to antimicrobial agents
Antimicrobial agent
2005
(n [ 3758)
2006
(n [ 6072)
2007
(n [ 6524)
2008
(n [ 6678)
2009
(n [ 7992)
2010
(n [ 9225)
2011
(n [ 11 860)
2012
(n [ 14 154)
2013
(n [ 16 794)
2014
(n [ 16 511)
Amikacin 11.9 7.6 8.0 8.2 7.6 7.4 5.9 5.4 4.0 4.0
Gentamicin 61.0 54.9 55.0 52.6 52.4 52.2 48.2 48.0 47.3 46.6
Piperacillin 76.9 76.9 76.0 77.1 76.9 75.3 75.7 76.0 73.5 71.6
Piperacillin/tazobactam 6.2 4.0 5.5 4.2 4.6 5.9 5.2 4.8 3.9 3.4
Cefazolin 68.8 66.5 70.2 70.6 72.7 69.2 70.8 70.5 72.8 71.1
Cefuroxime 52.8 55.5 61.6 63.0 63.9 64.1 63.9 63.3 64.4 62.8
Cefotaxime 52.2 54.9 60.4 62.3 63.2 63.2 63.1 63.2 62.9 62.0
Ceftazidime 14.9 17.0 19.9 22.6 28.5 30.7 30.9 30.0 28.4 28.8
Cefepime 31.2 32.2 35.4 37.6 40.2 42.1 40.7 38.5 31.6 28.1
Cefoperazone/sulbactam 9.0 5.8 2.9 4.0 5.3 6.5 7.9 7.6 6.0 5.4
Cefoxitin 13.0 11.6 10.8 10.9 10.9 13.5 12.0 15.5 16.3 13.6
Imipenem 1.1 1.4 0.7 1.2 1.7 1.6 1.0 0.9 1.0 0.9
Meropenem 1.4 0.8 0.8 0.9 1.0 1.4 1.2 1.0 3.0 1.0
Ertapenem 2.4 2.5 1.5 1.6 1.2
Ciproﬂoxacin 68.0 61.7 59.2 58.7 58.7 59.5 57.7 58.1 58.3 58.9
Sulfamethoxazole/
trimethoprim
71.0 66.0 66.5 64.7 66.2 66.8 66.4 60.1 57.6 59.1
Fosfomycina 6.7 6.5 6.5 7.3
aResults only from urine isolates.
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FIG. 1. Rates of methicillin-resistant Staphylococcus aureus, extended-
spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumo-
niae, imipenem-resistant Gram-negative bacilli clinical isolates from
2005 to 2014.
TABLE 3. Resistance rates (%) of Klebsiella pneumoniae to antimicr
Antimicrobial agent
2005
(n [ 2234)
2006
(n [ 3452)
2007
(n [ 3037)
2008
(n [ 3435)
2009
(n [
Amikacin 29.0 19.8 18.0 15.9 15.1
Gentamicin 41.0 35.7 34.8 34.9 35.0
Piperacillin 58.0 58.4 59.1 59.5 56.1
Piperacillin/tazobactam 28.0 18.9 17.4 15.5 15.0
Cefazolin 59.6 58.7 59.5 59.2 57.3
Cefuroxime 49.4 51.7 52.0 52.9 50.8
Cefotaxime 49.9 52.3 51.5 52.2 50.5
Ceftazidime 34.5 33.3 31.4 34.1 32.9
Cefepime 33.0 34.1 32.0 31.7 33.1
Cefoperazone/sulbactam 23.0 12.7 8.7 8.8 10.8
Cefoxitin 16.0 18.3 17.4 17.5 13.0
Imipenem 3.0 3.4 2.4 4.0 4.9
Meropenem 2.9 2.6 2.9 3.8 4.8
Ciproﬂoxacin 41.0 32.1 31.1 29.9 27.8
Sulfamethoxazole/
trimethoprim
49.0 43.9 44.2 43.9 45.4
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Imipenem, meropenem and ciproﬂoxacin resistance rates
essentially ﬂuctuated around 1.0, 2.2 and 11%, respectively
(Table 2).
Klebsiella pneumoniae
The rate of ESBL-producing isolates decreased from 39.1% in
2005 to 29.9% in 2014 (p <0.001). A marked increase of
resistance was seen for imipenem and meropenem from 2.4 to
10.5% and from 2.6 to 13.4%, respectively. Piperacillin/tazo-
bactam and cefoperazone/sulbactam resistance levels decreased
from 28 to 13.9% and from 23 to 16.1%, respectively. Amikacin,
ciproﬂoxacin, ceftazidime and cefepime resistance levels
decreased from 29 to 9%, 41 to 22.4%, 34.5 to 29.1% and 33.0
to 22.6%, respectively. Cefotaxime resistance levels were stable
from 49.9 to 48.1%. Gentamicin and cefoxitin resistance rates
essentially ﬂuctuated around 16.4 and 9.6%, respectively
(Table 3).obial agents
4556)
2010
(n [ 5529)
2011
(n [ 6981)
2012
(n [ 9621)
2013
(n [ 12 121)
2014
(n [ 11 308)
14.4 12.4 11.4 10.1 9.0
34.0 33.5 28.5 28.2 24.6
57.5 55.2 52.0 50.2 48.2
16.6 15.9 14.1 13.8 13.9
56.8 56.9 53.7 59.1 52.3
50.3 50.4 50.1 48.9 47.3
49.9 49.3 48.5 48.4 48.1
35.4 34.8 32.6 30.6 29.1
35.1 34.5 29.6 25.7 22.6
14.8 15.8 17.0 15.8 16.1
21.7 19.0 16.0 15.5 12.1
8.8 9.3 8.9 10.0 10.5
8.9 9.4 10.8 13.5 13.4
30.1 27.5 24.1 22.4 22.4
44.3 46.4 31.9 30.1 29.2
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The resistance level decreased for all of antimicrobial agents. A
marked decrease of resistance was seen for gentamicin and
piperacillin from 46 to 14.9% and from 44 to 19.8%, respec-
tively. Piperacillin/tazobactam, ciproﬂoxacin and amikacin
resistance levels decreased from 34 to 14.4%, from 32 to 14.9%
and from 23 to 9.4%, respectively (Table 4).
Acinetobacter baumannii
A marked resistance increase was seen for imipenem and
meropenem from 31% in 2005 to 62.4% in 2014, from 39% in
2005 to 66.7% in 2014, respectively. Cefoperazone/sulbactam
and minocycline resistance levels increased from 25 to 37.7%
and from 33 to 49.7%, respectively. Amikacin and sulfameth-
oxazole/trimethoprim resistance levels decreased from 61 to
47.4% and from 69 to 50.5%, respectively (Table 5).
Staphylococcus aureus
A marked decrease of the methicillin resistance rate was seen
from 69% in 2005 to 44.6% in 2014 (Fig. 1). No isolate was
found resistant to vancomycin, linezolid or teicoplanin. ForTABLE 4. Resistance rates (%) of Pseudomonas aeruginosa to antim
Antimicrobial agent
2005
(n [ 2323)
2006
(n [ 4752)
2007
(n [ 3988)
2008
(n [ 4130)
200
(n [
Amikacin 23.0 16.5 18.7 15.5 14.8
Gentamicin 46.0 44.2 39.2 27.7 26.9
Piperacillin 44.0 46.5 40.1 32.6 30.9
Piperacillin/tazobactam 34.0 38.9 32.8 25.9 24.1
Cefoperazone 41.0 45.3 40.3 32.3 29.1
Cefoperazone/sulbactam 23.0 25.7 22.8 14.8 18.2
Ticarcillin/clavulanic acid 51.0 56.2 50 43.6 41.1
Ceftazidime 29.0 28.3 29.3 21.0 20.3
Cefepime 28.0 26.3 26.0 17.6 19.7
Aztreonam 37.0 32.8 31.2 26.3 29.9
Imipenem 31.0 42.8 35.8 30.5 30.5
Meropenem 32.0 34.1 28.5 24.5 25.2
Ciproﬂoxacin 32.0 30.7 29.8 14.8 23.9
Levoﬂoxacin
TABLE 5. Resistance rates (%) of Acinetobacter baumannii to antim
Antimicrobial agent
2005
(n [ 2095)
2006
(n [ 2968)
2007
(n [ 3157)
2008
(n [ 3625)
2009
(n [
Amikacin 61.0 58.4 51.8 57.1 49.4
Gentamicin 71.0 67.4 62.5 64.8 59.9
Piperacillin 70.0 65.9 66.7 70.7 69.7
Piperacillin/tazobactam 59.0 56.3 54.4 62.4 58.5
Cefoperazone/sulbactam 25.0 11.6 5.3 14.6 23.6
Ceftazidime 59.0 55.7 52.4 58.7 56.2
Cefepime 62.0 54.8 55.0 61.6 57.7
Aztreonam 84.0 80.1 91.4 81.7 92.6
Imipenem 31.0 30.1 35.3 48.1 50.0
Meropenem 39.0 40.9 39.9 49.3 52.4
Ciproﬂoxacin 62.0 61.8 60.0 66.9 63.0
Sulfamethoxazole/
trimethoprim
69.0 67.0 66.7 67.8 68.8
Minocycline 33.0 31.4 32.9 25.3 26.7
Polymyxin B
Polymyxin E
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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licemethicillin-resistant S. aureus isolates, a resistance increase was
seen for rifampin from 34.9 to 47.2%. Clindamycin and sulfa-
methoxazole/trimethoprim resistance levels decreased from
90.1 to 52.9% and from 36.3 to 7.0%, respectively. Erythro-
mycin resistance levels decreased from 92.7 to 77.1% (Table 6).DiscussionThe trends of resistance levels among E. coli and K. pneumoniae
were similar. A decrease of resistance with time was seen for
amikacin, ciproﬂoxacin, piperacillin/tazobactam and cefoper-
azone/sulbactam and an increase in resistance was observed for
cefotaxime. For P. aeruginosa, resistance levels decreased for all
of antimicrobial agents, including imipenem and meropenem.
However, resistance of A. baumannii increased to many
important antimicrobial agents, especially imipenem and
meropenem.
Carbapenems are the most potent and reliable β-lactam
antibiotics for the treatment of serious infections caused by
multidrug-resistant Enterobacteriaceae [2,3]. However,icrobial agents
9
4912)
2010
(n [ 5080)
2011
(n [ 6012)
2012
(n [ 7271)
2013
(n [ 8257)
2014
(n [ 7471)
15.3 14.3 13.5 11.0 9.4
25.9 23.5 20.9 17.5 14.9
30.3 29.3 24.6 23.7 19.8
23.9 21.7 17.5 16.7 14.4
29.5 31.7 34.5 29.8 30.9
17.9 19.8 19.8 16.6 15.5
41.2 38.7 38.3 35.5 35.1
21.6 19.5 19.6 24.4 18.7
19.3 19.0 18.3 16.4 16.0
32.4 38.9 29.4 26.2 26.2
30.8 29.1 29.1 27.1 26.6
25.8 25.0 27.1 25.1 24.3
22.4 20.8 17.9 16.8 14.9
26.1 24.6 20.5 16.5 12.9
icrobial agents
4796)
2010
(n [ 5523)
2011
(n [ 6723)
2012
(n [ 8739)
2013
(n [ 10 120)
2014
(n [ 8769)
51.7 48.7 40.2 46.0 47.4
64.0 64.8 60.9 63.3 62.5
69.4 69.8 69.6 67.0 71.0
64.6 63.9 58.3 63.2 62.4
30.7 39.1 33.0 36.4 37.7
64.2 71.9 64.5 69.2 68.0
64.1 64.6 59.4 64.5 67.6
84.7 92.2 72.6 82.2 76.4
57.1 60.4 56.8 62.8 62.4
58.3 61.4 61.4 59.4 66.7
68.3 67.3 60.8 66.1 65.4
73.4 70.9 56.8 51.7 50.5
25.2 27.3 42.2 41.8 49.7
1.6 1.4 0.7 1.9
6.3 2.6 0.0 0.0
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This is an open access articarbapenem resistance has been emerging and increasing in a
wide variety of Enterobacteriaceae species worldwide [4–7]. In
Europe, ﬁve of the 24 reporting countries had signiﬁcant
increasing trends of carbapenem-resistant K. pneumoniae in the
period between 2009 to 2012. None of the countries had a
signiﬁcant decreasing trend. In 2012, the percentage of
K. pneumoniae isolates resistant to carbapenems ranged from
zero (seven countries) to 60.5% (Greece), and for Acinetobacter
spp., more than half of isolates reported by these countries
were resistant to all antimicrobial groups under surveillance
(carbapenems, ﬂuoroquinolones and aminoglycosides) [4].
The results of the present study show that the carbapenem
resistance rates among K. pneumoniae and A. baumannii are
higher in comparison with antibiotic resistance in E. coli and
P. aeruginosa. Because carbapenem-resistant Gram-negative
bacilli are usually extensively drug resistant, infections caused by
these strains present a serious clinical challenge for physicians in
healthcare settings [8]. Treatment options for these infections
are limited, and few clinical data are available on which to base
antibiotic recommendations. Moreover, the use of inappro-
priate empirical antibiotic therapy or delayed appropriate
antibiotic therapy can lead to worse outcomes. Previous studies
have found crude mortality rates ranging from 30 to 44% for
diverse infections caused by carbapenem-resistant Enter-
obacteriaceae [9]. These results suggest that prompt detection is
critical for containing carbapenem-resistant strains and pre-
venting nosocomial transmission. Because only few novel anti-
microbials are in development for the treatment of these
extensively drug-resistant infections, further studies should
focus on the judicious use of available antibiotics and imple-
mentation of strict infection control measures to avoid the
rapid spread or clonal dissemination of carbapenems-resistant
K. pneumoniae and A. baumannii in healthcare facilities [10].
Although many surveillance projects of antibiotic resistance
are carried out, they usually cover only shorter time periods
[11,12]. We found large ﬂuctuations over time in our study,
indicating that it is important to perform antibiotic resistance
surveillance studies over longer time periods. This is especially
important for some antimicrobial agents, such as carbapenems.
These ﬂuctuations might be explained partly as a result of
outbreaks of nosocomial infections. The present study has two
limitations. One is that participating hospitals do not cover all of
the provinces or cities in China. Currently, there are 34
provinces or cities in China, and the CHINET surveillance
system covers 14 of them. Another limitation is we collected
only the routine susceptibility testing results by Kirby-Bauer or
automated systems. In the future, we should expand this sur-
veillance system to cover at least one hospital in each province
or city. We also have a plan to collect the clinical isolates from
each hospital involving the CHINET surveillance system and tolf of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S9–S14
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
S14 Clinical Microbiology and Infection, Volume 22 Number S1, March 2016 CMIcarry out agar dilution or broth microdilution to determine the
minimum inhibitory concentration of antimicrobial agents, since
the reporting of minimum inhibitory concentration values is
important for hospital-based surveillance and will improve the
reliability of the current surveillance system [13].Transparency declarationSupported in part by Pﬁzer Investigator Initiated Research
(grant WI207259) and the National Natural Science Foundation
of China (grant 81273559). The funders had no role in study
design, data collection and analysis, decision to publish or
preparation of the manuscript. All authors report no conﬂicts
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